# A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

> **NCT01113034** · PHASE1 · COMPLETED · sponsor: **Ansun Biopharma, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Asthma
- Bronchiectasis

## Interventions

- **DRUG:** DAS181 dry powder, formulation F02
- **DRUG:** Respitose ML006 (DMV-Fonterra)

## Key facts

- **NCT ID:** NCT01113034
- **Lead sponsor:** Ansun Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-08-22
- **Final completion:** 2011-08-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113034, "A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01113034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*